Prostate Cancer Therapeutics Market to 2019 – Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

Publisher Name :
Date: 20-Nov-2013
No. of pages: 107

GBI Research has released the pharmaceutical report – “Prostate Cancer Therapeutics Market to 2019 – Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”. The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.

Scope

  • A brief introduction to prostate cancer, including the disease’s pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.
  • In-depth analysis of drugs available for the treatment of prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
  • Comprehensive review of the pipeline for prostate cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
  • Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth.
  • Discussion of the licensing and co-development deals landscape in prostate cancer, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals.

Reasons to Buy

  • Understand the different levels of prostate cancer therapies, from early-stage prostate cacner to metastatic and castrate-resistant prostate cancer.
  • Understand the vast scope and diversity of the pipeline, including which molecule types and mechanisms of action are prominent.
  • Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for prostate cancer therapeutics.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the prostate cancer therapeutics market.

Prostate Cancer Therapeutics Market to 2019 – Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Pathophysiology and Etiology 9
2.2 Epidemiology 11
2.3 Disease Progression 13
2.4 Treatment 15

3 Marketed Products 19
3.1 Hormonal Therapies 19
3.1.1 Zoladex (Goserelin) – AstraZeneca 19
3.1.2 Lupron Depot (Leuprolide acetate) – Abbvie 21
3.1.3 Triptorelin 22
3.1.4 Firmagon (degarelix) – Ferring 22
3.1.5 Casodex (Bicalutamide) 23
3.1.6 Summary 23
3.2 Chemotherapy agents 24
3.2.1 Taxotere (Docetaxel) – Sanofi 24
3.2.2 Jevtana (Cabazitaxel) – Sanofi 25
3.3 Therapeutic Vaccines 26
3.3.1 Provenge (sipuleucel-T) – Dendreon 26
3.4 Targeted therapies (Second Generation Anti-androgens) 27
3.4.1 Zytiga (Abiraterone acetate) – Janssen 27
3.4.2 Xtandi (Enzalutamide) – Astellas/Medivation 27
3.5 Bone Metastasis Treatments 28
3.5.1 Xofigo (Radium 223) – Bayer/Algeta 28
3.5.2 Xgeva (denosumab) – Amgen 29
3.5.3 Zometa (zoledronic acid) – Novartis 29
3.6 Heat Map for Marketed Products 30

4 Prostate Cancer Developmental Pipeline 33
4.1 Overall Pipeline 33
4.2 Mechanisms of Action 35
4.3 Clinical Trials 36
4.3.1 Attrition Rate 36
4.3.2 Enrollment 38
4.3.3 Duration 41
4.4 Key Late-Stage Pipeline Molecules 43
4.4.1 Cometriq (Cabozantinib) – Exelixis 43
4.4.2 OGX-011 (custirsen sodium) – Teva 43
4.4.3 TAK-700 (orteronel) – Takeda 44
4.4.4 ProstAtak (AdvTk+ valcyclovir) – Advantagene 44
4.4.5 ProstVac – Bavarian Nordic 44
4.4.6 Tasquinimod – Active Biotech 45
4.4.7 Yervoy (Ipilimumab) – Bristol-Myers Squibb 46
4.4.8 ARN-509 – Aragon Pharmaceuticals, Johnson and Jonhson 46

5 Market Forecast to 2019 47
5.1 Global 47
5.1.1 Treatment Usage Patterns 47
5.1.2 Market Size 49
5.2 North America 50
5.2.1 US 50
5.2.2 Canada 52
5.3 Five European Markets 54
5.3.1 Treatment Usage Patterns 54
5.3.2 Annual Cost of Therapy 56
5.3.3 Market Size 57
5.4 Japan 58
5.4.1 Treatment Usage Patterns 58
5.4.2 Market Size 59

6 Prostate Cancer Therapeutics: Drivers and Barriers 60
6.1 Drivers 60
6.1.1 Major Unmet Treatment Needs of Late Stage Prostate Cancer Patients 60
6.1.2 Increasing Disease Population 60
6.1.3 New Drugs Entering the Market 60
6.1.4 Rapid and Robust Uptake of Recently Approved High-Cost Therapies 60
6.1.5 Rapid Inflation Rate for Specialty Pharmaceutical Products in the US 60
6.1.6 Market Capture of Previously Untreated Patient Segments 61
6.2 Barriers 61
6.2.1 Uncertain Treatment Algorithm 61
6.2.2 Uptake Limited by High Prices for New Products 61
6.2.3 Patent Expiry of Taxotere 61
6.2.4 Intensifying Competition Acting as a Barrier to Market Capture 61

7 Licensing and Co-development Deals Analysis 62
7.1 Licensing Deals 62
7.1.1 Algeta Enters into Licensing Agreement with Bayer Schering for Xofigo 65
7.1.2 Sanofi-Aventis Enters into a Licensing Agreement with Oxford BioMedica 65
7.1.3 Novacea Enters Into Licensing Agreement With Schering-Plough For Asentar 65
7.1.4 Teva Pharma Enters into a Licensing Agreement with Oncogenex Pharma for OGX-011 65
7.1.5 Hoffman La Roche Enters into a Licensing Agreement with Inovio Pharmaceuticals for Prostate Cancer and Hepatitis B Immunotherapy Products 66
7.1.6 Colby Pharmaceutical Company Enters into a Licensing Agreement with MannKind for Cancer Immunotherapy Products 66
7.1.7 Ipsen Enters into a Licensing Agreement with GTx 66
7.1.8 Protox Therapeutics Enters into a Licensing Agreement with Kissei Pharma 67
7.1.9 AEterna Zentaris Enters Into License And Collaboration Agreement With Nippon Kayaku For Ozarelix 67
7.1.10 Orion Corporation Enters Into Agreement With Indevus Pharmaceuticals 67
7.2 Co-Development Deals 68
7.2.1 Medivation Enters into Co-Development Agreement with Astellas Pharma 69
7.2.2 Takeda Pharma Enters into an Agreement with Cell Genesys 69
7.2.3 Active Biotech Enters into Co-Development Agreement with Ipsen 69

8 Appendix 70
8.1 Market Definitions 70
8.2 Abbreviations 70
8.3 Sources 73
8.4 Sources for Marketed Products Heat Map 78
8.5 Scientific Support 78
8.6 Research Methodology 78
8.6.1 Coverage 79
8.6.2 Secondary Research 79
8.6.3 Therapeutic Landscape 79
8.6.4 Epidemiology-Based Forecasting 80
8.6.5 Market Size by Geography 81
8.6.6 Geographical Landscape 82
8.6.7 Pipeline Analysis 82
8.6.8 Competitive Landscape 82
8.6.9 Expert Panel Validation 82
8.7 All Publicly Announced Pipeline Products, by Phase 83
8.7.1 Discovery 83
8.7.2 Preclinical/IND-Filed 85
8.7.3 Phase I 94
8.7.4 Phase II 97
8.7.5 Phase III/Pre-Registration 101
8.7.6 Undisclosed Stage of Development 103
8.8 Tabular Forecast Data 103
8.8.1 Global 103
8.8.2 US 104
8.8.3 UK 104
8.8.4 France 105
8.8.5 Germany 105
8.8.6 Italy 106
8.8.7 Spain 106
8.8.8 Japan 107
8.8.9 Canada 107
8.9 Disclaimer 107

List of Tables

Table 1: Prostate Cancer Therapeutics, Prostate Cancer Risk Factors 10
Table 2: Prostate Cancer Therapeutics, Prostate Cancer Staging 13
Table 3: Prostate Cancer Therapeutics, Abbreviations 70
Table 4: Prostate Cancer Therapeutics, Sources for Heat Map 78
Table 5: Prostate Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 83
Table 6: Prostate Cancer Therapeutics, Global, All Pipeline Products (Preclinical/IND Filed), 2013 85
Table 7: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013 94
Table 8: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 97
Table 9: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase III/Pre-Registration), 2013 101
Table 10: Prostate Cancer Therapeutics, Global, All Pipeline Products (Undisclosed Stage of Development), 2013 103
Table 11: Prostate Cancer, Leading Eight Markets, Market Forecast, 2012–2019 103
Table 12: Prostate Cancer, US, Market Forecast, 2012–2019 104
Table 13: Prostate Cancer, UK, Market Forecast, 2012–2019 104
Table 14: Prostate Cancer, France, Market Forecast, 2012–2019 105
Table 15: Prostate Cancer, Germany, Market Forecast, 2012–2019 105
Table 16: Prostate Cancer, Italy, Market Forecast, 2012–2019 106
Table 17: Prostate Cancer, Spain, Market Forecast, 2012–2019 106
Table 18: Prostate Cancer, Japan, Market Forecast, 2012–2019 107
Table 19: Prostate Cancer, Canada, Market Forecast, 2012–2019 107

List of Figures

Figure 1: Prostate Cancer Therapeutics: Percentage of Men Diagnosed with Prostate Cancer in the US, by Age, 2005–2009 11
Figure 2: Prostate Cancer Therapeutics: Average Number of New Cases and Age-Specific Incidence Rates per 100,000 Population, UK, 2008–2010 12
Figure 3: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stages I and II) 15
Figure 4: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stage III) 15
Figure 5: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stage IV) 16
Figure 6: Prostate Cancer Therapeutics, Sales of Zoladex ($m), 2000–2012 20
Figure 7: Prostate Cancer Therapeutics, Sales of Lupron Depot ($m), 2009–2012 21
Figure 8: Prostate Cancer Therapeutics, Sales of Taxotere ($bn), 2004–2012 24
Figure 9: Prostate Cancer Therapeutics: Heat Map (mCRPC) 31
Figure 10: Market for Prostate Cancer, Global, Pipeline Overview, 2013 34
Figure 11: Market for Prostate Cancer, Global, Mechanisms of Action, 2013 35
Figure 12: Market for Prostate Cancer, Global, Clinical Trial Failure Rates, 2006–2013 36
Figure 13: Market for Prostate Cancer, Global, Clinical Trial Failure Rates (Molecule Type), 2006–2013 37
Figure 14: Market for Prostate Cancer, Global, Clinical Trial Failure Rates (Mechanism of Action), 2006–2013 38
Figure 15: Market for Prostate Cancer, Global, Clinical Trial Enrollment by Product (Molecule Type), 2006–2013 39
Figure 16: Market for Prostate Cancer, Global, Clinical Trial Enrollment by Product (Mechanism of Action), 2006–2013 40
Figure 17: Market for Prostate Cancer, Global, Clinical Trial Duration (Molecule Type), 2006–2013 41
Figure 18: Market for Prostate Cancer, Global, Clinical Trial Duration (Mechanism of Action), 2006–2013 42
Figure 19: Prostate Cancer Therapeutics: Top Eight Major Markets, Prevalence Populations, 2012–2019 48
Figure 20: Prostate Cancer Therapeutics: Top Eight Major Markets, Market Forecast ($bn), 2012–2019 49
Figure 21: Prostate Cancer Therapeutics, US, Treatment Usage Patterns, 2012–2019 50
Figure 22: Prostate Cancer Therapeutics: US, Market Forecast ($m), 2012–2019 51
Figure 23: Market for Prostate Cancer Therapeutics to 2019, Canada, Treatment Usage Patterns, 2012–2019 52
Figure 24: Prostate Cancer Therapeutics: Canada, Market Size ($m), 2012–2019 53
Figure 25: Prostate Cancer Therapeutics: Leading Five European Markets, Treatment Usage Patterns, 2012–2019 55
Figure 26: Prostate Cancer Therapeutics: Leading Five European Markets, Annual Cost of Therapy, 2012–2019 56
Figure 27: Prostate Cancer Therapeutics: Leading Five European Countries, Market Size ($m), 2012–2019 57
Figure 28: Prostate Cancer Therapeutics: Japan, Treatment Usage Patterns, 2012–2019 58
Figure 29: Prostate Cancer Therapeutics: Japan, Market Size ($m), 2012 – 2019 59
Figure 30: Market for Prostate Cancer, Global, Licensing Deals, 2006–2012 62
Figure 31: Market for Prostate Cancer, Global, Licensing Deals, 2006–2012 63
Figure 32: Market for Prostate Cancer, Global, Licensing Deals, 2006–2012 64
Figure 33: Market for Prostate Cancer, Global, Co-Development Deals, 2006–2012 68
Figure 34: Market for Prostate Cancer, Global, Co-Development Deals, 2006–2012 68
Figure 35: GBI Research Market Forecasting Model 81

  • Global Stem Cell Therapy Industry Witnesses Steady Growth
    Stem cell research which is one of the most contemporary areas of biology has developed rapidly in the last couple of years. Increased funding in stem cell research by both government and private organizations is one of the main drivers in the stem cell therapy industry. Stem cells are used in various medical therapies such [...]
  • Global Lubricant Market Driven by Increased Demand in Automotive Industry
    With growth in the automobile industry, the demand for lubricants has also increased. The robust growth in manufacturing with increase in industrial production, particularly in countries such as China and India are also fueling the demand for lubricants. In 2013, the global market for lubricants had reached a value of 123.64 billion USD. By 2020, [...]
  • Global Cybersecurity Market Driven by Increase in Cyber Attacks
    In recent years, the global market for cybersecurity has grown steadily, with the rapid adoption of cloud-based services. As more and more corporate and government organizations are realizing the importance of protecting data and intellectual property, the market for cybersecurity is going to expand. In 2014, the global market for cybersecurity was valued at 95.60 [...]
  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Liposarcoma – Pipeline Review, H2 2014
    Published: 14-Nov-2014        Price: US $2000 Onwards        Pages: 78
    Global Markets Direct's, ‘Liposarcoma - Pipeline Review, H2 2014', provides an overview of the Liposarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Liposarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involve......
  • Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 – Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies
    Published: 31-Oct-2014        Price: US $4995 Onwards        Pages: 98
    GBI Research, the leading business intelligence provider, has released its latest research, ""Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies"", which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology,......
  • Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 – New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options
    Published: 31-Oct-2014        Price: US $4995 Onwards        Pages: 109
    GBI Research, a leading business intelligence provider, has released its latest research report, "Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options", which provides in-depth insight into the indication. It provides estimates of market size for 2013 along with forecasts until 2020 for the eight major developed markets, which comprises the US, UK, France, Germany, Italy, Spain, Japan and C......
  • Osteosarcoma – Pipeline Review, H2 2014
    Published: 31-Oct-2014        Price: US $2000 Onwards        Pages: 90
    Global Markets Direct's, ‘Osteosarcoma Pipeline Review, H2 2014', provides an overview of the Osteosarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involv......
  • Frontier Pharma: Non-Small Cell Lung Cancer – Identifying and Commercializing First-in-Class Innovation
    Published: 31-Oct-2014        Price: US $6995 Onwards        Pages: 93
    Large Degree of Innovation in NSCLC Pipeline The NSCLC pipeline currently has 389 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market comprises primarily ineffective chemotherapies that target tubulin or DNA replication, the pipeline shows an incredibly diverse range of therapies targeting multiple signaling pathways and molecules integral to cancer development. Thi......
  • Metastatic Prostate Cancer – Pipeline Review, H2 2014
    Published: 31-Oct-2014        Price: US $2000 Onwards        Pages: 89
    Global Markets Direct's, ‘Metastatic Prostate Cancer Pipeline Review, H2 2014', provides an overview of the Metastatic Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press re......
  • Soft Tissue Sarcoma – Pipeline Review, H2 2014
    Published: 31-Oct-2014        Price: US $2000 Onwards        Pages: 224
    Global Markets Direct's, ‘Soft Tissue Sarcoma Pipeline Review, H2 2014', provides an overview of the Soft Tissue Sarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also revie......
  • Squamous Cell Carcinoma – Pipeline Review, H2 2014
    Published: 31-Oct-2014        Price: US $2000 Onwards        Pages: 145
    Global Markets Direct's, ‘Squamous Cell Carcinoma Pipeline Review, H2 2014', provides an overview of the Squamous Cell Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. I......
  • Cutaneous T-Cell Lymphoma – Pipeline Review, H2 2014
    Published: 31-Oct-2014        Price: US $2000 Onwards        Pages: 149
    Global Markets Direct's, ‘Cutaneous T-Cell Lymphoma Pipeline Review, H2 2014', provides an overview of the Cutaneous T-Cell Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press relea......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs